PH26569A - Veterinary treatment - Google Patents

Veterinary treatment Download PDF

Info

Publication number: PH26569A
Authority: PH; Philippines
Prior art keywords: infection; days; ppm; radical; feed
Prior art date: 1987-11-11

Application number

PH37795A

Other languages

English (en)

Inventor

Lincoln Dassanayake

Original Assignee

Cooper Animal Health Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-11-11

Filing date

1988-11-10

Publication date

1992-08-19

1988-11-10 Application filed by Cooper Animal Health Limited filed Critical Cooper Animal Health Limited

1992-08-19 Publication of PH26569A publication Critical patent/PH26569A/en

Links

XZJAKURZQBNKKX-QFQDJZPHSA-N (3e)-3-[(2s)-1-hydroxy-2-[(1s,2s,6r)-2-[(e)-3-hydroxy-2-[(2r,3r,6s)-6-[(e,3s)-3-[(2r,3s,5r)-5-[(1s)-1-methoxyethyl]-3-methyloxolan-2-yl]but-1-enyl]-3-methyloxan-2-yl]prop-1-enyl]-6-methylcyclohexyl]propylidene]oxolane-2,4-dione Chemical compound O1[C@@H]([C@H](C)OC)C[C@H](C)[C@@H]1[C@@H](C)\C=C\[C@H]1O[C@@H](C(\CO)=C\[C@@H]2[C@H]([C@H](C)CCC2)[C@H](C)C(\O)=C\2C(OCC/2=O)=O)[C@H](C)CC1 XZJAKURZQBNKKX-QFQDJZPHSA-N 0.000 claims abstract description 42
208000015181 infectious disease Diseases 0.000 claims abstract description 42
241000589893 Brachyspira hyodysenteriae Species 0.000 claims description 18
238000000034 method Methods 0.000 claims description 8
231100000252 nontoxic Toxicity 0.000 claims description 2
230000003000 nontoxic effect Effects 0.000 claims description 2
241000282887 Suidae Species 0.000 abstract description 23
150000001875 compounds Chemical class 0.000 abstract description 19
241001465754 Metazoa Species 0.000 abstract description 14
241000282898 Sus scrofa Species 0.000 abstract description 13
208000001848 dysentery Diseases 0.000 abstract description 13
230000000694 effects Effects 0.000 abstract description 8
241000192125 Firmicutes Species 0.000 abstract description 2
230000003115 biocidal effect Effects 0.000 abstract description 2
229950002881 tetronasin Drugs 0.000 abstract description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 2
-1 alkali metal salts Chemical class 0.000 description 27
239000003814 drug Substances 0.000 description 27
229940079593 drug Drugs 0.000 description 25
239000004189 Salinomycin Substances 0.000 description 13
KQXDHUJYNAXLNZ-XQSDOZFQSA-N Salinomycin Chemical compound O1[C@@H]([C@@H](CC)C(O)=O)CC[C@H](C)[C@@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 KQXDHUJYNAXLNZ-XQSDOZFQSA-N 0.000 description 13
229960001548 salinomycin Drugs 0.000 description 13
235000019378 salinomycin Nutrition 0.000 description 13
229930182504 Lasalocid Natural products 0.000 description 12
241000699670 Mus sp. Species 0.000 description 12
BBMULGJBVDDDNI-OWKLGTHSSA-N lasalocid Chemical compound C([C@@H]1[C@@]2(CC)O[C@@H]([C@H](C2)C)[C@@H](CC)C(=O)[C@@H](C)[C@@H](O)[C@H](C)CCC=2C(=C(O)C(C)=CC=2)C(O)=O)C[C@](O)(CC)[C@H](C)O1 BBMULGJBVDDDNI-OWKLGTHSSA-N 0.000 description 12
229960000320 lasalocid Drugs 0.000 description 12
125000000217 alkyl group Chemical group 0.000 description 11
125000004432 carbon atom Chemical group C* 0.000 description 11
150000003254 radicals Chemical class 0.000 description 10
206010012735 Diarrhoea Diseases 0.000 description 8
238000002474 experimental method Methods 0.000 description 7
229930191564 Monensin Natural products 0.000 description 6
GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 6
229960005358 monensin Drugs 0.000 description 6
GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 5
230000037396 body weight Effects 0.000 description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
238000012360 testing method Methods 0.000 description 5
241000252983 Caecum Species 0.000 description 4
235000021052 average daily weight gain Nutrition 0.000 description 4
210000004534 cecum Anatomy 0.000 description 4
125000000753 cycloalkyl group Chemical group 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
125000001624 naphthyl group Chemical group 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
125000003342 alkenyl group Chemical group 0.000 description 3
230000000052 comparative effect Effects 0.000 description 3
229960000946 dimetridazole Drugs 0.000 description 3
IBXPYPUJPLLOIN-UHFFFAOYSA-N dimetridazole Chemical compound CC1=NC=C(N(=O)=O)N1C IBXPYPUJPLLOIN-UHFFFAOYSA-N 0.000 description 3
235000021050 feed intake Nutrition 0.000 description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000011734 sodium Substances 0.000 description 3
238000010998 test method Methods 0.000 description 3
UURAUHCOJAIIRQ-QGLSALSOSA-N tiamulin Chemical compound CCN(CC)CCSCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 UURAUHCOJAIIRQ-QGLSALSOSA-N 0.000 description 3
229960004885 tiamulin Drugs 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
206010018910 Haemolysis Diseases 0.000 description 2
239000004721 Polyphenylene oxide Substances 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
230000000721 bacterilogical effect Effects 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000003651 drinking water Substances 0.000 description 2
235000020188 drinking water Nutrition 0.000 description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
125000001188 haloalkyl group Chemical group 0.000 description 2
230000008588 hemolysis Effects 0.000 description 2
125000002768 hydroxyalkyl group Chemical group 0.000 description 2
230000001524 infective effect Effects 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
229920000570 polyether Polymers 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 2
239000000725 suspension Substances 0.000 description 2
XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 description 1
125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241000486634 Bena Species 0.000 description 1
208000034598 Caecitis Diseases 0.000 description 1
101100190462 Caenorhabditis elegans pid-1 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000224483 Coccidia Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241001134665 Streptomyces longisporoflavus Species 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
241000589886 Treponema Species 0.000 description 1
239000004182 Tylosin Substances 0.000 description 1
229930194936 Tylosin Natural products 0.000 description 1
208000021017 Weight Gain Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
238000002814 agar dilution Methods 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
125000004183 alkoxy alkyl group Chemical group 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
125000005210 alkyl ammonium group Chemical group 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
125000004103 aminoalkyl group Chemical group 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
239000008280 blood Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
125000005242 carbamoyl alkyl group Chemical group 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
125000004181 carboxyalkyl group Chemical group 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
235000021051 daily weight gain Nutrition 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
238000001514 detection method Methods 0.000 description 1
125000004663 dialkyl amino group Chemical group 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
235000012631 food intake Nutrition 0.000 description 1
125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
125000004438 haloalkoxy group Chemical group 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
JCYWCSGERIELPG-UHFFFAOYSA-N imes Chemical class CC1=CC(C)=CC(C)=C1N1C=CN(C=2C(=CC(C)=CC=2C)C)[C]1 JCYWCSGERIELPG-UHFFFAOYSA-N 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
150000002923 oximes Chemical class 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000002460 polyether antibiotic agent Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
229960000268 spectinomycin Drugs 0.000 description 1
229960000887 spectinomycin hydrochloride Drugs 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
125000005208 trialkylammonium group Chemical group 0.000 description 1
WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
229960004059 tylosin Drugs 0.000 description 1
235000019375 tylosin Nutrition 0.000 description 1
150000003673 urethanes Chemical class 0.000 description 1
238000005303 weighing Methods 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Fodder In General (AREA)
Cephalosporin Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Feed For Specific Animals (AREA)

PH37795A 1987-11-11 1988-11-10 Veterinary treatment PH26569A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB878726384A GB8726384D0 (en)	1987-11-11	1987-11-11	Veterinary treatment

Publications (1)

Publication Number	Publication Date
PH26569A true PH26569A (en)	1992-08-19

Family

ID=10626769

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH37795A PH26569A (en)	1987-11-11	1988-11-10	Veterinary treatment

Country Status (11)

Country	Link
US (1)	US4999374A (fr)
EP (1)	EP0316163B1 (fr)
JP (1)	JP2706494B2 (fr)
AT (1)	ATE87478T1 (fr)
AU (1)	AU608093B2 (fr)
CA (1)	CA1318601C (fr)
DE (1)	DE3879877T2 (fr)
DK (1)	DK627188A (fr)
GB (1)	GB8726384D0 (fr)
IE (1)	IE63427B1 (fr)
PH (1)	PH26569A (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9806029D0 (en) *	1998-03-20	1998-05-20	Merck & Co Inc	8a-Azalides as veterinary antimicrobial agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4331658A (en) *	1977-05-31	1982-05-25	Eli Lilly And Company	Method of treating swine dysentery with antibiotic A-32887
GB2027013B (en) *	1978-08-03	1983-03-30	Ici Ltd	Compound m 139603 from streptomyces longisporoflavus and its use in ruminants
EP0070622B1 (fr) *	1981-07-16	1987-01-14	Imperial Chemical Industries Plc	Dérivés de M. 139,603 servant comme promoteurs de croissance
US4537956A (en) *	1983-11-23	1985-08-27	Hoffmann-La Roche Inc.	Antibiotics X-14889 A, C and D
ES8802229A1 (es) *	1985-04-30	1988-04-16	Glaxo Group Ltd	Un procedimiento para preparar nuevos derivados lactonicos macrociclicos.
JP6254307B2 (ja)	2016-02-25	2017-12-27	株式会社荏原製作所	めっき装置に使用される基板ホルダの漏れ検査方法

1987
- 1987-11-11 GB GB878726384A patent/GB8726384D0/en active Pending
1988
- 1988-11-10 IE IE336988A patent/IE63427B1/en not_active IP Right Cessation
- 1988-11-10 DE DE8888310571T patent/DE3879877T2/de not_active Expired - Fee Related
- 1988-11-10 CA CA000582789A patent/CA1318601C/fr not_active Expired - Fee Related
- 1988-11-10 DK DK627188A patent/DK627188A/da not_active Application Discontinuation
- 1988-11-10 JP JP63284814A patent/JP2706494B2/ja not_active Expired - Lifetime
- 1988-11-10 AT AT88310571T patent/ATE87478T1/de active
- 1988-11-10 PH PH37795A patent/PH26569A/en unknown
- 1988-11-10 AU AU25007/88A patent/AU608093B2/en not_active Ceased
- 1988-11-10 EP EP88310571A patent/EP0316163B1/fr not_active Expired - Lifetime
- 1988-11-14 US US07/270,002 patent/US4999374A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE3879877T2 (de)	1993-07-08
US4999374A (en)	1991-03-12
JP2706494B2 (ja)	1998-01-28
IE63427B1 (en)	1995-04-19
DE3879877D1 (de)	1993-05-06
JPH01153631A (ja)	1989-06-15
EP0316163B1 (fr)	1993-03-31
EP0316163A2 (fr)	1989-05-17
AU2500788A (en)	1989-05-25
CA1318601C (fr)	1993-06-01
GB8726384D0 (en)	1987-12-16
EP0316163A3 (en)	1990-06-27
DK627188A (da)	1989-05-12
IE883369L (en)	1989-05-11
ATE87478T1 (de)	1993-04-15
AU608093B2 (en)	1991-03-21
DK627188D0 (da)	1988-11-10

Publication	Publication Date	Title
CA1297410C (fr)	1992-03-17	Compositions non-antibacteriennes de tetracycline possedant des proprietes anti-collagenolytiques, procede de fabrication et mode d'utilisation
JPH0335796A (ja)	1991-02-15	環状デプシペプチド物質およびその製造法、ならびにそれを含有する駆虫剤
NZ337080A (en)	2001-03-30	Oral preparation containing xanthophylles such as astaxanthin to helicobacter sp.infection
CN110201035A (zh)	2019-09-06	一种禽用植物精油组合物及其制备方法和应用
EP0290998B1 (fr)	1992-08-12	Composition contre la coccidiose
UA56173C2 (uk)	2003-05-15	Спосіб лікування ветеринарних захворювань
EP0009686B1 (fr)	1982-06-23	Composition anti-bactérienne contenant un dérivé de l'acide phosphonique
Vebmeulen et al.	1954	Experimental urolithiasis VIII: Furadantin in treatment of experimental Proteus infection with stone formation
US5721242A (en)	1998-02-24	Antibiotic combination
CA1318601C (fr)	1993-06-01	Utilisation de la tetronasine et d'analogues de celle-ci contre la dysenterie porcine
EP0213692B1 (fr)	1990-09-26	Utilisation de l'hygromycine et de l'épihygromycine pour le traitement de la dysenterie du porc
EP0621783A1 (fr)	1994-11-02	Formulations pharmaceutiques comprenant un sel d'acide clavulanique et un derive d'erythromycine
CN115093974B (zh)	2023-07-25	一种深海枝孢菌及其发酵物在制备抗菌药物中的应用
EP0369503B1 (fr)	1992-12-23	Méthode pour contrôler pneumocystis carinii
JP5758602B2 (ja)	2015-08-05	ホスホマイシンを有効成分とする魚類のエドワジエラ症治療剤
US6328989B1 (en)	2001-12-11	Use of bicozamycin for the manufacture of a medicament for treating infections with enterohemorrhagic e. coli
CN121337815A (zh)	2026-01-16	熊果酸或熊果酸衍生物在制备抗鸡球虫病饲料或抗鸡球虫病药物中的应用
Craven	1995	Salmonella typhimurium, hydrophobic antibiotics, and the intestinal colonization of broiler chicks
CN121987653A (zh)	2026-05-08	一种复方中药及其在制备抗柔嫩艾美耳球虫或治疗球虫病药物中的应用
Van Ogtrop et al.	1991	Modulation of the intestinal flora of mice by treatment with aztreonam and tigemonam
Hewitt	1950	Use of antibiotics in the treatment of experimental diphtheria infections
Hashizume et al.	1987	Penetration of imipenem and other antibiotics into inflammatory exudate and their efficacy in pseudomonas infection in the rat granuloma pouch model
JPS634526B2 (fr)	1988-01-29
JPS6160840B2 (fr)	1986-12-23
WO1991015208A1 (fr)	1991-10-17	Traitement veterinaire